Bridges is a new educational podcast miniseries where co-hosts, Dr. Matthew Lunning and Dr. Tara Graff, bring together voices from across the lymphoma care spectrum. Each episode features candid conversations with a diverse range of clinicians, offering practical insights into current topics in lymphoma. With Dr. Graff practicing in the community setting at Mission Cancer & Blood and Dr. Lunning in academic medicine at the University of Nebraska, Bridges explores the dynamic between academic and community approaches—working to close the gap and foster collaboration in patient care.
This episode is not meant to be used for medical advice and is intended for educational purposes only. Speakers were compensated by ADC Therapeutics for their time. The views expressed in this series do not reflect the views of the speaker's employer. This podcast may include discussion of investigational agents that may not be applicable or approved in your country.
Episode 4 - Guiding principles when sequencing treatments in DLBCL
Gain practical insights into treatment sequencing in the evolving DLBCL landscape. In this episode, Dr. Marin Xavier shares her approach to navigating novel therapies—such as antibody drug conjugates (ADCs) and bispecifics—with a focus on patients who may not be ready for CAR T-cell therapy. Learn how she makes real-world decisions in a complex and rapidly changing field.
Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood
Guest: Dr. Marin Xavier, Hematologist and Oncologist, Scripps Health, San Diego
24 Nov 2025
Episode 3 - Managing novel DLBCL therapies in the community - what good looks like
Integrating novel therapies like bispecific antibodies (BsAbs) and antibody drug conjugates (ADCs) into community oncology practices can be a complex process. On this episode of Bridges, Dr. Lunning and Dr. Graff speak with Dr. Iqra Choudary about how she integrated BsAbs and ADCs into her practice with a proactive multidisciplinary team, strong safety protocols, comprehensive staff training, and strategic hospital partnerships.
Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood
Guest: Dr. Iqra Choudary, board certified in Internal Medicine, Hematology-Oncology Associates of Central New York
24 Nov 2025
Episode 2 - The future is now-combination therapies in DLBCL
Interested in novel combination therapies for patients with diffuse large B-cell lymphoma (DLBCL)? Dr. Marie Hu joins the podcast to share her perspectives on emerging treatments and the impact of stronger academic-community collaborations on patient care for relapsed and refractory patients with DLBCL.
Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood
Guest: Dr. Marie Hu, Assistant Professor of Medicine, University of Minnesota
24 Nov 2025
Episode 1 - Evolution of Antibody Drug Conjugates
Join us for a high-level look at antibody drug conjugates (ADCs) in lymphoma treatment. Dr. Weiyun Ai provides a detailed overview of ADCs—a pioneering method that can change how lymphoma is treated. Learn how they target cancer, overcome obstacles, and pave the way for developing new combination therapies.
Co-hosts: Dr. Matthew Lunning, MD, University of Nebraska Medical Center, and Dr. Tara Graff, MD, Mission Cancer & Blood
Guest: Dr. Weiyun Ai, Professor of Medicine, University of California, San Francisco
Reach and audience
Public platform figures. Ratings count people who left a rating, not total listeners.
Apple Podcasts (US)
5.0 / 5
3 ratings
Contact Bridges - Advances in Cancer Therapeutics
Guest appearances
Books guests
Based on episode analysis; this does not confirm that the show is currently accepting guests.
Host of Bridges - Advances in Cancer Therapeutics?
Claim your podcast to manage its listing and keep your show details accurate.
Pod Engine is an independent podcast discovery and analytics service and is not affiliated with or endorsed by this podcast. Artwork and show content belong to their owners. Full legal notice.
Explore this show Podcast research with Pod Engine